HaeseongSeongParkMDMPH

Oncology • Boston, MA

Gastrointestinal Cancer

Physician

Join to view full profile

Dr. Park is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Park's full profile

Already have an account?

Office
450 Brookline Ave
Boston, MA 02215
Phone+1 617-632-4500

Fax+1 617-632-5370

Education & Training

University of Texas M D Anderson Cancer CenterFellowship, Investigational Cancer Therapeutics Fellowship In Early Drug Development, 2014 - 2015
Virginia Commonwealth University Health SystemFellowship, Hematology and Medical Oncology, 2011 - 2014
Virginia Commonwealth University Health SystemResidency, Internal Medicine, 2008 - 2011
Seoul National University College of MedicineClass of 2006

Certifications & Licensure

MA State Medical License 2022 - 2025
MO State Medical License 2015 - 2023
VA State Medical License 2008 - 2015
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Ramucirumab Plus Irinotecan for Previously Treated Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma Start of enrollment: 2017 Nov 01
Completed
Phase 2
Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by Surgery Start of enrollment: 2018 Apr 20
Withdrawn
Phase 1, Phase 2
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer Start of enrollment: 2019 Oct 10
Recruiting
Phase 1, Phase 2
Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors Start of enrollment: 2019 Dec 04
Active, not recruiting
Phase 1
Roles: Contact
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene Start of enrollment: 2022 Oct 05
Recruiting
Phase 1
Roles: Principal Investigator, Contact
Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L) Start of enrollment: 2019 Jul 22
Active, not recruiting
Phase 2
Roles: Contact, Sub-Investigator
Join now to see all

Publications & Presentations

PubMed

First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.
Nehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson, Haeseong Park, Ding Wang
Clinical Cancer Research. 2024-12-16
Phase 1b study to assess the safety, tolerability, and clinical activity of pamiparib in combination with temozolomide in patients with locally advanced or metastatic ...
Agostina Stradella, Melissa Johnson, Sanjay Goel, Haeseong Park, Nehal Lakhani
Cancer Medicine. 2024-07-01
1 citations
PD-L1 has a heterogeneous and dynamic expression in gastric cancer with implications for immunoPET.
Dina Ibrahim, Cristina Simó, Emma L Brown, Shayla Shmuel, Sandeep Surendra Panikar
Frontiers in Immunology. 2024-01-01

Journal Articles

FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers
Haeseong Park, Andrea Wang-Gillam, Caron Rigden, Katrina S Pedersen, Nikolaos A Trikalinos, JAMA Oncology

Lectures

Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.
2019 ASCO Annual Meeting - 6/1/2019

Authored Content

FOLFIRINOX for the Treatment of Advanced Gastroesophageal CancersMay 2020